Etoposide phosphate, the water soluble prodrug of etoposide

Pharmacy World and Science

Volumn 18, Issue 5, 1996, Pages 163-170

  Witterland, A H I ^a,b   Koks, C H W ^a,b   Beijnen, J H ^a,b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b NONE

Author keywords

alkaline phosphatase; etoposide; etoposide phosphate; mechanism of action; pharmaceutical formulation; pharmacokinetics; prodrug

Indexed keywords

ETOPOFOS; ETOPOSIDE; PRODRUG;

ALLERGIC REACTION; ALOPECIA; BIOEQUIVALENCE; BONE MARROW SUPPRESSION; CANCER; CLINICAL TRIAL; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG RESPONSE; DRUG STABILITY; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS, PHASE I; ETOPOSIDE; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; PRODRUGS; SOLUBILITY; WATER;

EID: 0029856304     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00820727     Document Type: Review

References (22)

1. Stahelin HF, von Wartburg A. The chemical and biological route from podophyllotoxin glucoside to etoposide: Ninth Cain Memorial Award Lecture. Cancer Res 1991;51:5-15.
2. O'Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE. Drug therapy. Etoposide (VP-16-213). Current status of an active anticancer drug. N Engl J Med 1985;312:692-700.
3. Henwood JM, Brogden RN. Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs 1990;39(3):438-90.
4. Beijnen JH, Beijnen-Bandhoe AU, Dubbelman AC, Van Gijn R, Underberg WJM. Chemical and physical stability of etoposide and teniposide in commonly used infusion fluids. J Parenteral Science & Technology 1991;45:108-12.
5. Investigator brochure: BMY-40481 Etoposide phosphate. Wallingford, CT, Bristo-Myers Squibb 1991.
6. Beijnen JH, Holthuis JJM, Kerkdijk HG, van der Houwen OACJ, Paalman ACA, Bult A. Degradation kinetics of etoposide in aqueous solution. Int J Pharm 1988; 41:169-78.
7. Webster LK, Crinis NA, Davis JR, Millward MJ. Conversion of etoposide phosphate to etoposide under ambulatory infusion condition, J Oncol Pharm Practic 1995; 1: 33-6.
8. Senter PD, Saulnier MG, Schreiber GJ, Hirschberg DL, Brown JP, Hellstrom KE. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci USA 1988;85:4842-6.
9. Rose WC, Basler GA, Trail PA, Saulnier M, Crosswell AR, Casazza AM. Preclinical antitumor activity of a soluble etoposide analog, BMY-40481-30. Invest New Drugs 1990 8:S25-S32.
10. Schacter LP, Igwemezie LN, Seyedsadr M, Morgenthien E, Randolph J, Albert E. Clinical and pharmacokinetic overview of parenteral etoposide phosphate. Cancer Chemother Pharmacol 1994;34(suppl):S58-S63.
11. Harris H. The human alkaline phosphatases: what we know and what we don't know. Clin Chim Acta 1989;186:133-50.
12. Slevin ML, Clark PI, Joel SP, Malik S, Osborne RJ, Gregory WM. A randomized trial to evaluate the effect of schedule on the acitivity of etoposide in small-cell lung cancer. J Clin Oncol 1989;7(9):1333-40.
13. Clark PI, Slevin ML, Joel SP, Osborne RJ, Talbot DI, Johnson PWM. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 1994;12(7):1427-35.
14. Greco FA. Future directions for etoposide therapy. Cancer 1991;67(suppl):315-18.
15. Slevin ML, Joel SP, Whomsley R, Devenport K, Harvey VJ, Osborne RJ. the effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation. Cancer Chemother Pharmacol 1989;24:329-331.
16. Waits ThM, Johnson DH, Hainsworth JD, Hande KR, Thomas M, Greco A. Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial. J Clin Oncol 1992;10:292-6.
17. Hande KR, Krozely MG, Greco FA, Hainswort JD, Johnson DH. Bioavailability of low-dose oral etoposide. J Clin Oncol 1993;11:374-7.
18. Thompson DS, Hainsworth JD, Hande KR, Holzmer MC, Greco FA. Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study. J Clin Oncol 1993;11:1322-8.
19. Minami H, Shimokata K, Saka H, Saito H, Ando Y, Senda K. Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer. J Clin Oncol 1993;11:1602-8.
20. Schwinghammer TL, Reilly M. Cracking of ABS plastic devices usd to infuse undiluted etoposide injection. Am J Hosp Pharm 1988;45:1277.
21. Hoetelmans RMW, Schornagel JH, ten Bokkel Huinink WW, Beijnen JH. Hypersensitivity reactions to etoposide. Ann Pharmacother 1996;30367-71.
22. Hudson MM, Weinstein HJ, Donaldson S, Greenwald C, Kun L, Tarbell NJ. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin'S disease. J Clin Oncol 1993;11:1080-4.